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Objectives. To characterize clinical outcomes in patients with intermediate or high-risk endometrial carcinoma who underwent
surgical staging with or without para-aortic lymphadenectomy. Methods. This is a retrospective cohort study of patients with
intermediate or high-risk endometrial adenocarcinoma who underwent surgical staging with (PPALN group) or without (PLN)
para-aortic lymphadenectomy. Data were collected, Kaplan-Meier curves were generated, and univariate and multivariate analyses
performed to compare differences in adjuvant therapy, disease recurrence, disease-free survival (DFS), and overall survival (OS).
Results. 118 patients were included in the PPALN group and 139 in the PLN group. Patients in the PPALN group were more likely
to receive adjuvant vaginal brachytherapy (25.4% versus 11.5%, OR = 2.5, 𝑃 = 0.03) and less likely to receive adjuvant multimodal
combination therapy (17.81% versus 28.8%, OR = 0.28, 𝑃 = 0.002). DFS was improved in the PLN group as compared to PPALN
(80% versus 62%, 𝑃 = 0.02). OS was equivalent (𝑃 = 0.93). Patients in the PPALN group who had less than 10 para-aortic nodes
removed were twice as likely to recur than patients who had 10 or more para-aortic nodes or patients in the PLN group (HR 2.08,
CI 1.20–3.60, 𝑃 = 0.009). Conclusions. Patients in the PLN group were more likely to receive multimodal adjuvant therapy and
had better DFS than the PPALN group. Pelvic lymphadenectomy followed by adjuvant radiation and chemotherapy may represent
an effective treatment option for patients with intermediate or high-risk disease. If systematic para-aortic lymphadenectomy is
performedandlessthan10para-aorticlymphnodesareobtained,multimodalityadjuvanttherapyshouldbeconsideredtoimprove
DFS.
1. Introduction
The landmark study GOG 33 described the patterns of
spread in endometrial carcinoma and concluded that clinical
staging is inaccurate as 22% of clinical stage I patients were
assignedahighersurgicalstage[1].Assuch,theInternational
Federation of Gynecology and Obstetrics (FIGO) changed
the endometrial cancer staging system from clinical to sur-
gical [2]. Conventionally, surgical staging includes a total
hysterectomy,bilateralsalpingooophorectomy,andretroperi-
toneal pelvic and para-aortic lymphadenectomy. Although
pelvic washings are no longer part of the 2009 FIGO surgical
staging system, they are still collected at time of surgery [2].
Multivariate analysis of GOG 33 indicated 3 uterine
factorsasindependentpredictorsofnodalmetastasis,includ-
ing tumor grade, depth of myometrial invasion, and the
presence of intraperitoneal disease [3]. Using these factors
as predictors of disease aggressive behavior, endometrial2 International Journal of Surgical Oncology
carcinoma is often divided into low, intermediate, and high-
risk diseases [3]. Typically, patients with intermediate and
high-risk diseases undergo surgical staging. However, the
beneficial effect of complete, systematic lymphadenectomy
is debatable. Several studies reported increased morbidity
associatedwiththeadditionofretroperitoneallymphadenec-
tomy to the surgical procedure including increased mean
blood loss, increased risk of blood transfusion, increased
operative time and longer hospital stay [4, 5]. Addition-
ally, lymphadenectomy increases the risk of postoperative
fever, incision site infection, lymphocyst formation, lower-
extremity edema, embolic events, gastrointestinal obstruc-
tion, and perioperative mortality [6]. Notably, the addition
of para-aortic lymph node dissection further increases the
surgical morbidity. Cragun et al. reported increased blood
loss, transfusion rates, and length of hospital stay in patients
undergoingbothpelvicandpara-aorticlymphadenectomyas
compared to patients undergoing pelvic lymphadenectomy
alone [7].
We designed a study examining the role of para-aortic
lymphadenectomy in the surgical staging of patients with
intermediate and high-risk endometrial adenocarcinomas.
Ourobjectivesweretoassesswhetherornotpara-aorticlym-
phadenectomy impacts administration of adjuvant therapy,
disease recurrence, disease-free survival (DFS), and overall
survival (OS).
2. Materials and Methods
2.1. Study Design. This a retrospective cohort study inves-
tigating patients who underwent surgical staging for newly
diagnosed high-grade endometrioid, serous, or clear cell
endometrial adenocarcinoma at Brigham and Women’s Hos-
pital and Massachusetts General Hospital, Harvard Medi-
cal School, Boston, MA, USA, between January 2000 and
December 2010. Institutional review board (IRB) approval
was obtained from the hospitals’ ethics board. Eligible
patients were identified using the hospitals’ pathology data
base and data points were obtained from the patients’ elec-
tronic medical records.
2.2.StudyPopulation. Thefirststudygroupincludedpatients
who underwent primary surgical staging including total
abdominal, laparoscopic or robotic hysterectomy, bilateral
salpingooophorectomy, washings, and pelvic and para-aortic
lymphadenectomy (PPALN group). The second study group
includedpatientswhounderwentasimilarstagingprocedure
withtheexceptionofthepara-aorticlymphadenectomy(PLN
group).Datawerecollectedfromthepatients’hospitalcharts
a n da n a l y z e du s i n ga p p r o p r i a t es t a t i s t i c a lt e s t s .
2.3. Outcome Measures. The primary outcome measure of
this study was to compare overall survival (OS) between
t h et w os t u d yg r o u p st oe v a l u a t et h ei m p a c tt h a tp a r a -
aortic lymphadenectomy has on OS. The secondary outcome
measures were to examine whether the absence of a para-
aortic lymphadenectomy impacts administration of adjuvant
therapy, disease recurrence, or disease-free survival (DFS).
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Figure1:Kaplan-Meierdisease-freesurvivalestimate.PPALN<10
∗
versus PLN
† or PPALN+10
∗∗ logrank test: HR 2.34, CI 1.36–4.02,
𝑃 = 0.002.
∗Patients in the pelvic and para-aortic Lymph node
(PPALN) group with less than 10 para-aortic lymph nodes retrieved
at time of dissection.
∗∗Patients in the pelvic and para-aortic lymph
node (PPALN) group with 10 or more para-aortic lymph nodes
retrieved at time of dissection.
†Patients in the pelvic lymph node
(PLN) group.
2.4. Statistical Analysis. Chi-square, Fisher’s exact tests, and
𝑡-tests were used to compare the characteristics of patients
in the two study groups. Kaplan-Meier curves and Cox
proportional hazards models were used to compare OS and
DFS between the groups. Models were adjusted for age, year
of surgery, histology, lymphovascular invasion, myometrial
invasion, and adjuvant therapy. All analyses were performed
using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Population Characteristics. Ofallwomendiagnosedwith
endometrial carcinoma at Brigham and Women’s Hospital
and Massachusetts General Hospital, Boston, MA, USA,
between January 2000 and December 2010, 257 met our
inclusion criteria and were subjected to our final analysis.
The PPALN group was composed of 118 patients, while
139 patients underwent PLN. The mean age at time of
diagnosis in the PPALN group was 63.1, and in the PLN
group it was 67.1 (𝑃 = 0.002). Importantly, survival was
not significantly altered when controlling for the difference
in age. Demographic and clinical characteristics of the study
c o h o r ta r ep r o v i d e di nTable 1.
3.2. Clinical and Surgical Characteristics. The surgical stages
were similar between the PPALN group and the PLN group
(Table 1). Patients in the PLN group had higher rates of
papillaryseroushistology(32.4%versus19.7%,𝑃 = 0.02)a n d
lower rates of grade 3 endometrioidcarcinoma (23.7% versus
44.4%) than patients in the PPALN group. Risks of recur-
rence and DFS were not affected when controlling for the
differences in histology using multivariate analysis (Table 2).
The other histological subtypes were similar between the
two groups. Patients in the PPALN group had significantlyInternational Journal of Surgical Oncology 3
Table 1: Demographic and clinical characteristics of patients in the
PPALN and the PLN groups.
PPALN
∗
𝑁 = 118
PLN
∗∗
𝑁 = 139 𝑃 value
Age
Mean (SD) 63.1 (10.7) 67.1 (9.5) 0.002
Histology
Grade 3 endometrioid 52 (44.4%) 33 (23.7%) 0.002
Papillary serous 23 (19.7%) 45 (32.4%)
Clear cell 9 (7.7%) 15 (10.8%)
Grade 2 endometrioid 4 (3.4%) 2 (1.4%)
Mixed 25 (21.4%) 43 (30.9%)
Stage
I 66 (55.9%) 74 (53.2%) 0.33
II 7 (5.9%) 12 (8.6%)
III 35 (29.7%) 33 (23.7%)
IV 10 (8.5%) 20 (14.4%)
Lymphovascular invasion
No 52 (47.7%) 83 (64.8%) 0.008
Yes 57 (52.3%) 45 (35.2%)
Myometrial invasion
No 60 (52.6%) 88 (64.7%) 0.05
Yes 54 (47.4%) 48 (35.3%)
Intraoperative
complications
None 99 (86.1%) 124 (89.9%) 0.44
1 or more 16 (13.9%) 14 (10.1%)
Postoperative
complications
None 54 (46.6%) 79 (57.2%) 0.09
1 or more 62 (53.4%) 59 (42.8%)
∗Pelvic and para-aortic lymph node group.
∗∗Pelvic lymph node group.
higher lymphovascular space invasion (52.3% versus 35.2%,
𝑃 = 0.008) and higher outer half myometrial invasion (47.4%
versus 35.3%, 𝑃 = 0.05). Risks of recurrence and DFS were
not significantly affected when controlling for these variables
by multivariate analysis (Table 2). The intraoperative com-
plications studied included cystotomy, enterotomy, vascular
injury, ureteral injury, and intraoperative blood transfusion.
Postoperative complications studied included fever, blood
transfusion, paralytic ileus, small bowel obstruction, wound
cellulitis, deep wound infection, and reoperation within 28
days of original surgery. Intraoperative and postoperative
complication rates were equivalent between the groups (𝑃=
0.36 and 𝑃 = 0.09, resp.). The mean number of pelvic nodes
removed per patient in the PLN group was 10.7 (range 1–35).
The mean numbers of pelvic and para-aortic nodes in the
PPALN group were 16.1 (range 2–40) and 5.3 (range 1–19),
respectively.Forty-onepatients(29.4%)inthePLNgrouphad
positive pelvic lymph nodes (Table 3). In the PPALN group,
34 patients (28.8%) had positive pelvic lymph nodes, and 26
patients (22.03%) had positive para-aortic lymph nodes. Of
the 26 patients with positive para-aortic lymph nodes, 20
(16.9%) had concurrent positive pelvic lymph nodes, and 6
(5.08%) had negative pelvic lymph nodes (Table 3).
3.3. Treatment and Recurrence. Patients in the PPALN group
were more likely to receive adjuvant vaginal brachytherapy
(25.4% versus 11.5%, OR = 2.5, 𝑃 = 0.03)a n dl e s s
likely to receive adjuvant multimodal therapy consisting
of combined vaginal brachytherapy, pelvic radiation and
chemotherapy (17.8% versus 28.8%, OR = 0.28, 𝑃 = 0.0019)
(see Table 1(a) in Supplementary Material available online at
http://dx.doi.org/10.1155/2013/858916).PatientsinthePPALN
group were more likely to experience disease recurrence
than patients in the PLN group (38.9% versus 20.14%, 𝑃=
0.003).Variationinadjuvanttherapywasnotanindependent
p r e d i c t o ro fr e c u r r e n c e ,D F So rO S( s e eT a b l e s1 ( b )a n d
1(c) in Supplementary Material). The number of para-aortic
nodes removed at time of surgery was associated with
disease recurrence. Patients in the PPALN group who had
less than 10 para-aortic nodes removed were twice more
likely to recur than patients who had 10 or more para-
aortic nodes or patients in the PLN group (HR 2.34, CI
1.36–4.02, 𝑃 = 0.002)( Figure 1). As such, the number of
para-aortic lymph nodes obtained at time of surgery was
an independent factor associated with disease recurrence
and DFS (Table 2). Abdominal recurrences represented a
significantly increased portion of recurrences in the PLN
group compared to the PPALN group (53.6% versus 28.3%,
𝑃 = 0.03)( Table 4(a)). Recurrence patterns at other sites
including vagina, pelvis, pelvic lymph nodes, para-aortic
lymph nodes and extra-peritoneal sites were similar between
the groups (Table 4(a)). Cox proportional hazards model for
o v e r a l ls u r v i v a ls h o w e dn oa s s o c i a t i o nb e t w e e nr e c u r r e n c e
site and survival (Table 4(b)). These analyses were adjusted
f o ra g e( c o n t i n u o u s ) ,y e a ro fs u r g e r y( c o n t i n u o u s ) ,l y m p h
nodes (PLN and PALN), histology (endometrioid, mixed,
clear cell, and papillary serous), lymphovascular invasion,
and myometrial invasion.
3 . 4 .D i s e a s eF r e ea n dO v e r a l lS u r v i v a l .OS was similar
between the PLN and the PPALN groups (𝑃 = 0.93)
(Figure 2(a)). Patients in the PLN group had better DFS than
patients in the PPALN group (80% versus 62%, 𝑃 = 0.02)
(Figure 2(b)). The mean followup time was 32.4 months.
4. Discussion
Our study investigates the role and extent of retroperi-
toneal lymphadenectomy in the management of women with
intermediate and high-risk endometrial adenocarcinomas.
Women who underwent para-aortic lymph node dissections
hadanoverrepresentationofdeepmyometrialinvasion,lym-
phovascular invasion, and grade 3 endometrioid histology,
and they were less likely to undergo postoperative multi-
modalityadjuvanttherapy.Coxproportionalhazardsmodels
as well as multivariate analysis were adjusted for age, year4 International Journal of Surgical Oncology
Table 2: Disease-free survival analysis adjusting for the following variables: tumorhistology,lymphovascular invasion,myometrialinvasion,
and number of para-aortic lymph nodes.
No recurrence 𝑁 = 183 Recurrence 𝑁=7 4 Age-adjusted
HR (95% CI)
Fully adjusted
∗
HR (95% CI)
𝑃
Histology
Endometrioid/mixed 112 (61.5%) 52 (70.3%) 1.00 1.00
Clear cell 17 (9.3%) 7 (9.5%) 0.95 (0.42, 2.14) 1.33 (0.58, 3.05) 0.50
Papillary serous 53 (29.1%) 15 (20.3%) 0.64 (0.36, 1.15) 0.68 (0.37, 1.26) 0.23
Lymphovascular invasion
No 112 (67.1%) 23 (32.9%) 1.00 1.00
Yes 55 (32.9%) 47 (67.1%) 2.99 (1.82, 4.93) 1.67 (0.91, 3.07) 0.10
Myometrial invasion
No 121 (67.6%) 27 (38.0%) 1.00 1.00
Yes 58 (32.4%) 44 (62.0%) 2.76 (1.70, 4.45) 1.69 (0.93, 3.06) 0.08
Lymph nodes
PLN 111 (60.7%) 28 (37.8%) 1.00 1.00
PPALN < 10
∗ 56 (30.6%) 42 (56.8%) 2.16 (1.33, 3.52) 2.34 (1.36, 4.02) 0.002
PPALN ≥ 10
∗∗ 16 (8.7%) 4 (5.4%) 1.06 (0.37, 3.01) 1.36 (0.44, 4.24) 0.59
∗PPALN patients with less than 10 para-aortic nodes dissected.
∗∗PPALN patients with 10 or more dissected para-aortic nodes.
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Figure2:(a)Kaplan-Meieroverallsurvivalestimate.LogranktestPLNversusPPALN𝑃value=0.93.(b)Kaplan-MeierDisease-Freesurvival
estimate. PLN versus PPALN Logrank test 𝑃 value = 0.02.
of surgery, histology, lymphovascular invasion, myometrial
invasion and adjuvant therapy to control for the variations
within the groups. Multivariate analysis incorporating these
significant variables along with the extent of lymphadenec-
tomy confirmed that only para-aortic lymphadenectomy
yielding less than 10 nodes was associated with an increased
riskofrecurrenceanddecreasedPFS.NodifferenceinOSwas
observedbetweenthegroups.Thesedatasuggestthatlimited
para-aortic lymph node dissection may not obviate the need
for aggressive, multimodality adjuvant therapy based on
clinical risk factors.
The role of para-aortic lymph node dissection in the
staging of endometrial carcinoma is debatable. At our cen-
ter, the decision to perform systematic para-aortic nodal
dissection is largely surgeon dependent. Moreover, the
necessity of systematic para-aortic lymphadenectomy is
being challenged by some surgeons as they believe it
increases morbidity without added benefit. Notably, lym-
phatic drainage of uterine lesions confined to the corpus is
primarily to the external iliac and the obturator lymph nodes
[8]. In advanced disease, para-aortic nodal involvement
may occur via spread through the common iliac lymphatic
channels [8]. As such, para-aortic involvement often follows
pelvic nodal involvement. Abu-Rustum et al. examined the
incidence of isolated para-aortic nodal metastasis in the
setting of negative pelvic lymph nodes and found it was
approximately 1% in both low and high-grade diseases [9].
In our study, 6 of 118 patients (5.08%) in the PPALN groupInternational Journal of Surgical Oncology 5
Table 3: (a) Number of positive lymph nodes in the PLN and
PPALN groups. (b) Breakdown of pelvic and para-aortic nodal
metastasis in the PPALN group.
(a)
PPALN PLN
All <10 ≥10
Positive pelvic lymph
nodes
None 84 (71.2) 68 (69.4) 16 (80.0) 98 (70.5)
1 or more 34 (28.8) 30 (30.6) 4 (20.0) 41 (29.5)
Mean (SD) 1.0 (2.4) 1.1 (2.6) 0.4 (1.1) 0.5 (1.1)
Positive para-aortic
lymph nodes
None 92 (78.0) 75 (76.5) 17 (85.0) —
1 or more 26 (22.0) 23 (23.5) 3 (15.0) —
Mean (SD) 0.4 (0.9) 0.4 (1.0) 0.2 (0.4) —
(b)
PPALN
(𝑃 < 0.0001)
Negative
pelvic and
para-aortic
nodes
Positive
pelvic and
para-aortic
nodes
Positive
pelvic nodes
only
Positive
para-aortic
nodes only
118 (100) 78 (66.1) 20 (16.9) 14 (11.8) 6 (5.08)
hadpositivepara-aorticnodalmetastasiswithnegativepelvic
lymph nodes.
The therapeutic effects of lymphadenectomy are an issue
of great debate in the gynecologic oncology literature. Find-
ings from two large prospective randomized trials of pelvic
lymphadenectomy failed to demonstrate a clear therapeutic
benefit[10,11].Conversely,Marianietal.showedthatpatients
with poorly differentiated endometrial adenocarcinoma who
underwent retroperitoneal lymphadenectomy had an asso-
ciated survival advantage [12]. However, this advantage did
not extend to the addition of para-aortic lymphadenectomy
to the lymph node dissection [12]. Recently, the survival
effectofpara-aorticlymphadenectomyinendometrialcancer
(SEPAL) study aimed to examine whether complete, sys-
tematic para-aortic lymphadenectomy would have a survival
effect in patients with intermediate and high-risk endome-
trial carcinomas [13] .Th er e s u l t so ft h i sr e t r o s p e c t i v ec o h o r t
study showed an increased overall survival in patients who
had both pelvic and para-aortic lymph node dissection com-
pared to patients who underwent pelvic lymphadenectomy
alone. Notably, the average number of lymph nodes in this
study was 34 nodes in patients who had pelvic lymph node
dissection and 59 nodes in patients who had pelvic and para-
aortic lymph nodes dissection with an average of 24 para-
aorticnodes[13].Thesenumbersaresignificantlyhigherthan
the average nodal dissection quoted in most studies.
Interestingly, our results indicate that patients in the
PPALN grouphad an increaseddisease recurrencecompared
to patients in the PLN group. The number of para-aortic
lymph nodes retrievedat dissection was a significant variable
inpredictingDFS.Abu-Rustumetal.showedthatremovalof
10 or more regional lymph nodes was indicative of adequate
surgical staging [14]. Furthermore, Chan et al. noted an
improved DFS in patients with intermediate and high-risk
diseases who underwent extensive lymph node dissection
[15].Thesedatashowthatpatientswith10ormorepara-aortic
nodes had improved DFS compared to those who had less
than 10 nodes removed. Furthermore, patients in the PPALN
groupwhohad10ormorepara-aorticnodeshadsimilarDFS
to patients in the PLN group, while those with less than 10
nodeshadaworseDFSthanpatientsinthePLNgroup.These
data suggest that limited para-aortic nodal sampling may not
provide survival advantage and may negatively impact DFS.
Adjuvant treatment is an important consideration in
the management of women with endometrial carcinoma.
Th eS E P A Ls t u d yi n d i c a t e dt h a ta d j u v a n tc h e m o t h e r a p y
improvessurvivalinintermediateandhigh-riskdiseases[13].
The majority of these cancers are comprised of aggressive
histopathological types including high-grade endometrioid,
clear cell, and serous carcinomas. It is well established that
clear cell and serous endometrial carcinomas are highly
malignant, estrogen-independent tumors and are thus clas-
sified as type 2 carcinomas [16, 17]. These subtypes account
for 10% of endometrial malignancies but are responsible
for approximately 50% of relapses [16, 17]. Similarly, high-
grade endometrioid cancers often have an aggressive clinical
course. Voss et al. examined the immunohistochemical pat-
terns of grade 3 endometrioid carcinoma and found them to
be similar to those of clear cell and papillary serous carcino-
mas [18]. The authors concluded that grade 3 endometrioid
cancer may be better characterized as type 2 cancer and
shouldbetreatedwithsimilaradjuvanttherapytoserousand
clear cell carcinoma [18]. Given the aggressive tumor biology
of type 2 carcinoma, some authorities believe patients should
be managed with a limited staging procedure followed by
systemic therapy irrespective of stage. In our series, patients
inthePLNgroupweremorelikelytoreceivesystemictherapy
as compared to patients of similar stage in the PPALN group.
Giventhepresumedcomprehensivesurgicalstaging,patients
inthePPALNgroupwerelesslikelytoreceivecomprehensive
adjuvant therapy consisting of vaginal cuff brachytherapy,
pelvic radiation, and systemic chemotherapy.
Patients in the PPALN group experienced a decreased
D F St h a np a t i e n t si nt h eP L Ng r o u p .R e c u r r e n c e si nt h e
vagina, pelvis, pelvic lymph nodes, para-aortic lymph nodes,
and extraperitoneal sites were similar between the groups.
Interestingly, the absence of a para-aortic lymph node dis-
s e c t i o ni nt h eP L Ng r o u pd i dn o ti m p a c tt h er i s ko fp a r a -
aortic recurrence. Isolated para-aortic lymph node recur-
rence usually occurs in approximately 6% of women with
endometrial carcinoma [8]. Our results revealed 17 patients
( 6 . 6 % )w i t hp a r a - a o r t i cr e c u r r e n c e - 5i nt h eP L Ng r o u p
(3.59%) and 12 in the PPALN group (10.16%) (𝑃 = 0.39).
Importantly, patients who experienced disease recurrence
were successfully salvaged as the OS was similar between the
study groups.
The limitations of this study are inherent to its retro-
spective nature. Patients underwent surgical staging with
or without para-aortic lymph node dissection based on6 International Journal of Surgical Oncology
Table4:(a)DiseaserecurrencepatternsinthePPALNandthePLNgroups.(b)Overallsurvivalanalysisadjustingforrecurrencesiteamongst
patients who experienced a recurrence
∗.
(a)
PPALN
𝑁 = 118
PLN
𝑁 = 139
Chi-square
𝑃 value
Vagina
No 39 (84.8%) 24 (85.7%) 0.91
Yes 7 (15.2%) 4 (14.3%)
Pelvic lymph node
No 38 (82.6%) 24 (85.7%) 0.72
Yes 8 (17.4%) 4 (14.3%)
Pelvis
No 34 (73.9%) 22 (78.6%) 0.65
Yes 12 (26.1%) 6 (21.4%)
Para-aortic lymph node
No 33 (71.7%) 23 (82.1%) 0.31
Yes 13 (28.3%) 5 (17.9%)
Extraperitoneal
No 21 (45.7%) 12 (42.9%) 0.81
Yes 25 (54.3%) 16 (57.1%)
Abdomen
No 33 (71.7%) 13 (46.4%) 0.03
Yes 13 (28.3%) 15 (53.6%)
(b)
Alive
𝑁=6 3
Dead
𝑁=1 1
Age-adjusted HR
(95% CI)
Fully adjusted
∗ HR
(95% CI) 𝑃
Vagina
No 52 (82.5%) 11 (100.0%)
Yes 11 (17.5%) 0 (0%)
Pelvic lymph node
No 53 (84.1%) 9 (81.8%) 1.00 1.00
Yes 10 (15.9%) 2 (18.2%) 0.64 (0.12, 3.31) 0.22 (0.02, 2.43) 0.22
Pelvis
No 48 (76.2%) 8 (72.7%) 1.00 1.00
Yes 15 (23.8%) 3 (27.3%) 1.06 (0.28, 4.02) 1.41 (0.15, 13.1) 0.76
Para-aortic lymph node
No 48 (76.2%) 8 (72.7%) 1.00 1.00
Yes 15 (23.8%) 3 (27.3%) 0.46 (0.11, 1.93) 0.37 (0.04, 3.16) 0.36
Extraperitoneal
No 31 (49.2%) 2 (18.2%) 1.00 1.00
Yes 32 (50.8%) 9 (81.8%) 3.26 (0.69, 15.4) 10.9 (0.42, 285) 0.15
Abdomen
No 39 (61.9%) 7 (63.6%) 1.00 1.00
Yes 24 (38.1%) 4 (36.4%) 1.46 (0.39, 5.43) 1.19 (0.16, 8.87) 0.86
∗Adjustedforage(continuous),yearofsurgery(continuous),lymphnodes(PLNandPALN),histology(endometrioid/mixed,clearcell,andpapillary
serous), lymphovascular invasion, and myometrial invasion.International Journal of Surgical Oncology 7
recommendations by the attending surgeon. This decision
may have been influenced by preoperative biopsy results,
medical or surgical co-morbidities, and surgeon preferences
and practice. Patients in the PLN group were older, and
tumors in that group were less likely to invade the outer
myometrium or the lymphovascular space. To control for
the heterogeneity between the groups, multivariate statistical
analyses were preformed. Importantly, the heterogeneous
variables had no impact on DFS or OS. As such, the results
were statistically significant and consequently have clinical
relevance.
I nc o n c l u s i o n ,p a t i e n t si nt h eP L Ng r o u ph a di m p r o v e d
DFS than patients in the PPALN group. DFS was equivalent
b e t w e e np a t i e n t si nt h eP L Ng r o u pa n dp a t i e n t si nt h e
PALN group who had more than 10 para-aortic lymph nodes
removed. Notably, intermediate and high-risk endometrial
malignanciesoftenexhibitaggressivetumorbiologyandmay
require adjuvant therapy to decrease the risk of recurrence.
Importantly, patients in the PLN group were more likely to
receive multimodality adjuvant therapy than patients in the
PALN group, which may have contributed to their improved
s u r v i v a l .Th u s ,o p e r a t i v es t a g i n gw i t hp e l v i cl y m p h a d e n e c -
tomyalonefollowedbyadjuvantradiationandchemotherapy
may represent a safe and effective treatment option for
women with this disease. Alternatively, if systematic pelvic
and para-aortic lymphadenectomy is performed, thorough
nodal dissection is advocated with the goal of obtaining 10
or more nodes per lymphatic chain. If less than 10 para-
aortic lymph nodes are sampled, the dissection may be an
inadequate triage tool for adjuvant therapy. Hence, adjuvant
radiationtherapyandchemotherapyshouldbe consideredto
improve DFS.
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